Veru's experimental drug reduces hot flashes in men in mid-stage study [Reuters (UK)]
Veru Inc. (VERU)
Last veru inc. earnings: 2/12 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
verupharma.com/investors
Company Research
Source: Reuters
Veru's experimental drug reduces hot flashes in men in mid-stage study - Reuters 2 Min Read (Reuters) - Veru Inc said on Monday a higher dose of its experimental drug reduced hot flashes in men with advanced prostate cancer after six weeks of treatment, in a mid-stage study. The drug, zuclomiphene citrate, is a synthetic estrogen that aims to reduce the frequency of hot flashes, an unintended effect of androgen deprivation therapy which is a commonly used treatment for prostate cancer. There are currently no FDA-approved treatments on the market for hot flashes in men. Patients taking a 50 mg dosage of the oral treatment had reduced hot flashes after six weeks compared to placebo and the 10 mg dosage. The trial, which includes 93 patients, will continue for a total of 12 weeks. Veru expects to begin a late-stage trial for the drug in the first half of 2020, pending discussions with the U.S. Food and Drug Administration, Chief Executive Officer Mitchell Steiner told Reuters. There were
Show less
Read more
Impact Snapshot
Event Time:
VERU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERU alerts
High impacting Veru Inc. news events
Weekly update
A roundup of the hottest topics
VERU
News
- Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.MarketBeat
- Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeekGlobeNewswire
- Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight LossGlobeNewswire
- Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management CongressGlobeNewswire
- Veru to Present at the 2024 Cantor Global Healthcare ConferenceGlobeNewswire
VERU
Earnings
- 8/8/24 - Miss
VERU
Analyst Actions
- 11/6/24 - Oppenheimer Holdings Inc.
VERU
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- 11/4/24 - Form SC
- VERU's page on the SEC website